reports
- Guy Sips
- Hilde Van Boxstael
- Wim Lewi
- Guy Sips
Lotus Bakeries FIRST LOOK : Three Continents, One Momentum: Lotus Turn...
In FY25, Lotus Bakeries delivered a 10% revenue increase to a very nice € 1.355m (KBCSe 1.355m, CSS 1.346m), driven by continued strong volume growth in 2H25 for both Lotus Biscoff (57% of branded revenues, +13% y/y) and Lotus Natural Foods (25% of branded, +17% y/y). Lotus Bakeries highlighted that the partnerships with Mondelez advanced strongly, contributing positively to the 2025 revenue By the end of 2025, Biscoff production expanded to three continents. We welcome that the new production...
- Guy Sips
Melexis In rough weather, exaggeration only deepens the valley
Melexis enters 2026 with a message that is far from triumphant: the recovery is happening, but it remains “an uneven recovery”. 4Q25 delivered growth, yes—but only just—and once again China dictated the rhythm with swings that overshadow structural progress. We updated our model taking into account management insists that FY26 will mark the start of margin improvement, and while the yield normalization story is credible, it does little to offset the uncomfortable reality of flat sales in 1Q an...
- Guy Sips
X Fab Silicon Foundries EV FIRST LOOK : Cautious on near term given on...
We updated our model as 1Q26 revenue is expected to come in within the range of $190-200m (KBCS from the low of the markets ($200.6m while CSS was $ 213.4m) to $ 195m now with an EBITDA margin in the range of 18% and 21% (KBCSe new 21.2%). We regret X-FAB is not providing FY26 guidance at this time due to limited visibility and the current macroeconomic environment. We think CSS will have to lower FY26E forecast substantially (CSS was $ 916.6m sales and 26.3% EBITDA-margin) and as a result we lo...
- Kristof Samoy
Vopak First Reaction - Withdrawal of support by First Nation for REEF ...
Yesterday, Energynow.ca published an article on the withdrawal of support by the Metlakatla First Nation citizens of Canada. Supposedly the Metlakatla First Nation's decision to retract its backing for the nearly completed REEF export project is rooted in concerns that it was not informed of an exclusivity agreement granting REEF an export monopoly, which could harm its economic interests in the rival Trigon terminal where it holds a 10% stake. A recent BC Supreme Court ruling allowing Metlakatl...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Mathijs Geerts Danau
- Wim Lewi
- Kristof Samoy
Ekopak Delivery Waterkracht permit and Dutch wastewater plant acquisit...
Yesterday evening an article was published in the local Antwerp newspaper GVA. It stated Flemish Minister of the Environment Jo Brouns (CD&V) has granted a permit for the Waterkracht project. As a result, all chemical companies in the Port of Antwerp will use purified wastewater to cool their production processes starting at the end of 2027. Earlier on the target was to start commercial operations early 2027 and this is still reflected in our earnings model. We will overhaul our model once it is...
- Jacob Mekhael
Zealand Pharma Model update, multiple important catalysts ahead
We update our Zealand model following the company's recent CMD held in December 2025. Zealand outlined its plans to become a generational metabolic health company, as well as sharing clear targets with 5 product launches in the next 5 years, and to have 10+ clinical programs by 2030. Our model update incorporates adjusted milestone timing from Roche, removes dapiglutide, as well as a few small tweaks on the rare disease pipeline. All in all, this brings us to a new TP of DKK 960 (from DKK 1,120)...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update February 2026: Removing ASMi; Adding UCB
After today's changes (ASMi out, UCB in), we maintain a balanced approach in our Dynamic Top Pick List, with a particular emphasis on value stocks that have been overlooked. Our defensive holdings are overweight, including real estate, which stands to benefit from lower interest rates. We remove ASMi from our Dynamic Top Pick List as the recent share price performance has driven the valuation meaningfully ahead of fundamentals. Since early December, FY27 diluted EPS expectations have risen by a...
EVS EVS BROADCAST EQUIPMENT SA
UCB UCB S.A.
DIE D'IETEREN SA
SOF SOFINA SA
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
AED AEDIFICA SA
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
UCB Presents supportive three-year Bimzelx data in HS at EHSF
UCB announced that three-year data from the BE HEARD trials for Bimzelx in moderate to severe HS will be presented at the Conference of the European Hidradenitis Suppurativa Foundation EHSF, being held 4–6 February in Malta. The data show high rates of total HS resolution at 3 years, high rates of improvement from moderate or severe HS to mild disease, as well as strong draining tunnel resolution. This continues to highlight Bimzelx' benefit in this patient group, which we believe will further d...
- Guy Sips
Melexis FIRST LOOK: Remaining in an uneven recovery
Melexis saw in 4Q25 still a challenging and unstable environment as the automotive industry demand continues to be cautious and choppy between quarters. They indicated they remain in an uneven recovery. Melexis highlighted that -looking at FY26- 1Q is traditionally impacted by annual customer pricing agreements and seasonal factors such as Chinese New Year and sales patterns outside of automotive. In addition, this year demand is affected by recent changes in EV automotive regulations and purcha...
- Mathijs Geerts Danau
Onward Medical Announces enrolment of first participant in Empower BP ...
Onward announces enrolment of the first participant in the Empower BP trial. The trial evaluates the ARC-IM system to address blood pressure instability in SCI patients. We note that Onward plans an interim analysis of the efficacy results in 2H26, which could accelerate timelines if fewer total patients are required. Short-term, we look forward to the FY25 results to gain a view on the ARC-EX commercial launch (9M25: 70 devices sold). We reiterate our € 8.9 TP and BUY rating.
- Wim Hoste
Akzo Nobel Uninspiring 4Q & FY26 outlook, while Axalta merger can beco...
Akzo's 4Q25 results were roughly in line with previous quarters, with weak volumes and negative FX leading to a slight decline in adjusted EBITDA, despite sizeable efficiency improvement initiatives. 2026 is expected to bring more of the same, with Akzo forecasting flat volumes and an FY26 adjusted EBITDA that is guided to be up at least 2% (or at least 7% excluding negative FX and scope effects). With current efficiency improvement initiatives expected to have mostly run their course in 2027, t...
- Wim Lewi
Elia Group German government agrees on 25.1% Tennet stake
Yesterday, the German government (via KfW) secured a 25.1% "blocking minority" in TenneT's German operations. The €3.3bn deal ends years of negotiations between Germany and the Netherlands. The deal is struck at the same equity value following the capital contribution (46%) from ABP, GIC and Norges Bank in 09/25 at a total equity value of 13.3bn. TenneT NL will hold the remaining 28.9%. We understand from the Handelsblatt that KfW will invest an additional €1.7bn before 2035. TenneT GE will no...
- Guy Sips
- Jacob Mekhael
- Wim Hoste
- Wim Lewi
- Wim Lewi
Xior FY25 Results in line, visibility improves with 4% EPS growth till...
On 11/12/25, Xior already gave a heads up on the FY26 expected EPRA EPS of €2.30 and 4% growth yoy. This morning, Xior also issued a FY27e EPRA EPS of €2.40. Xior has stabilised its business and enjoys better visibility. The reported EPRA EPS25 of €2.21 came in line with their guidance and our €2.22 expectation. Xior NRI rose 7.2%, while like-for-like growth remained high at 5.43%. LTV% also fell below 50% at 49.7%. Xior expects growth thanks to a mix of factors: new assets + lfl growth of >4%...
- Jacob Mekhael
UCB Model update ahead of FY25 results
Following the second guidance upgrade for FY25 (announced 5 December 2025), we update our UCB model ahead of FY25 results. UCB now expects revenue to exceed €7.6bn, representing +24% y/y (previously at least €7bn). The upgraded guidance reflects - next to the continued growth of Rystiggo, Zilbrysq, Fintepla and Evenity – strong performance of Bimzelx, including a strong momentum in hidradenitis suppurativa (HS) and a favourable payer mix in the US. Our model update increases Bimzelx FY25 sales t...
- Wim Hoste
Akzo Nobel FIRST LOOK: 4Q EBITDA -4%, FY26 guidance slightly below exp...
4Q adjusted EBITDA dropped by 4% y/y and was in line with our forecast while being 2% below consensus. Akzo guides for a FY26 adj EBITDA at or above € 1.47bn, which is at the low end 2% below our forecast and 4% below consensus. The merger with Axalta is expected to close in late 2026 or early 2027. Taking into account the volatile track record and low structural growth, we maintain our Hold rating and € 65 target price.
- Wim Hoste
Titan Completion of acquisition of Vracs de L'Estuaire
Titan has completed the earlier announced acquisition of the cementitious business of Vracs de l'Estuaire. The acquisition complements Titan's European footprint and also fits well within TITAN's Forward 2029 Strategic plan which was presented in November 2025, and which targets to grow EBITDA by 62% to € 1bn by 2029 on a combination of organic growth initiatives and M&A in regions where the company has an established footprint and acquisitions offer sizeable synergies potential. Overall, TITAN ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.